This segment focuses on the research and development of therapeutics for various cancers, including prostate and breast cancer. The primary focus is on ART26.12, a fatty acid binding protein 5 (FABP5) inhibitor. Research and development activities include preclinical studies, clinical trials, and formulation development. Technologies used include small molecule drug development and analysis of lipid-signaling pathways. The goal is to improve patient outcomes by providing targeted therapies with fewer side effects. Market positioning involves competing with established cancer treatments while offering novel mechanisms of action. Future opportunities include expanding the pipeline to address additional cancer types and exploring combination therapies. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials to demonstrate efficacy and safety. Partnerships with research institutions like Trinity College Dublin support preclinical research and development efforts.

This segment is dedicated to developing treatments for mental health disorders, specifically focusing on Post-Traumatic Stress Disorder (PTSD). The primary product candidate is ART12.11, a synthetic cannabidiol cocrystal. Research and development activities include preclinical studies, clinical trials, and formulation development. Technologies used include cannabinoid-based drug development and analysis of lipid-signaling pathways. The aim is to improve patient outcomes by providing effective treatments for PTSD symptoms. Market positioning involves addressing the unmet needs of patients suffering from PTSD. Future opportunities include expanding the pipeline to address other mental health conditions and exploring combination therapies. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials to demonstrate efficacy and safety. Partnerships with research institutions support preclinical research and development efforts.

This segment focuses on the development of treatments for inflammatory bowel disease (IBD). The primary product candidate is ART12.11, a synthetic cannabidiol cocrystal. Research and development activities include preclinical studies, clinical trials, and formulation development. Technologies used include cannabinoid-based drug development and analysis of lipid-signaling pathways. The aim is to improve patient outcomes by providing effective treatments for IBD symptoms. Market positioning involves addressing the unmet needs of patients suffering from IBD. Future opportunities include expanding the pipeline to address other gastrointestinal conditions and exploring combination therapies. Regulatory and clinical aspects involve navigating FDA approval processes and conducting clinical trials to demonstrate efficacy and safety. Partnerships with research institutions support preclinical research and development efforts.